{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Blood Cancer Talks","title":"Episode 66. International Myeloma Society 2025 Annual Meeting Updates with Dr. Alfred Garfall: The Bispecific Bonanza","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/d32f56e4\"></iframe>","width":"100%","height":180,"duration":3136,"description":"This episode provides comprehensive coverage of key clinical trial updates from the 2025 International Myeloma Society (IMS) Annual Meeting in Toronto, with special focus on bispecific antibodies and novel immunotherapies across the multiple myeloma disease continuum—from smoldering disease through relapsed/refractory settings. Dr. Alfred Garfall provides expert commentary on study design, efficacy, safety considerations, and clinical implications.\n\nTopics Covered\n\n1. SMOLDERING MULTIPLE MYELOMA\n\nLINKER-SMM1\nPhase 2, open-label study of linvoseltamab monotherapy (200 mg) in patients with high-risk smoldering multiple myeloma by 20/2/20 or PETHEMA criteria, with 2-year treatment duration.\nDiscussion Points:\nAppropriateness of 2-year treatment duration for precursor condition\nEfficacy and MRD-negative rates\nSafety considerations in asymptomatic population\nPatient selection if available today\n\n2. NEWLY DIAGNOSED MULTIPLE MYELOMA\n\nMajesTEC-5\nPhase 2 trial evaluating three teclistamab-daratumumab-based induction regimens in 49 transplant-eligible NDMM patients, followed by auto-transplant and fixed-duration Tec-Dara maintenance.\nDiscussion Points:\nPost-induction MRD-negativity rates with Tec-DR and Tec-DVR\nGrade 3-5 infection rates and infection-related deaths\nQuestionable utility of bortezomib and need for ASCT with 100% MRD-negativity\nHigh infection prophylaxis requirements\n\nMagnetisMM-6\nPhase 1/2 dose-finding study of fixed-dose elranatamab 76 mg Q4W with Dara-Len in 37 transplant-ineligible NDMM patients (median age 75 years).\nDiscussion Points:\nVGPR or better rates\nSafety profile including infections and CRS/ICANS\nRisk of continuous therapy in elderly/frail population\n\nLINKER-MM4\nPhase 1/2 study of linvoseltamab monotherapy in NDMM with both transplant-eligible and transplant-ineligible pathways, exploring three dose levels (50, 100, 200 mg).\nDiscussion Points:\nEfficacy of single-agent Linvo in NDMM\nWhether any NDMM population could achieve long-term control with...","thumbnail_url":"https://img.transistorcdn.com/sqlYzk0Oxhchi1Lmft_9Md8dG97D7hyy2rwRG7COuc0/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzMyMDc4LzE2NTcz/MTQxMDUtYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}